BioSpace News Archive

BioLineRx Ltd., a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced that it has received a notification letter from the Nasdaq Stock Market LLC.

Iovance Biotherapeutics, Inc. announced that on May 16, 2024, the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance’s common stock to thirty new, non-executive employees.

A European Medicines Agency panel on Friday cited a possible but unconfirmed risk of cancer and recommended that hydroxyprogesterone caproate drugs be suspended from the European Union market.

Bayer on Thursday provided additional data on late-stage studies of its rival drug to Astellas’ Veozah, which met all primary endpoints.

Life science companies can protect intellectual property in multiple ways, including leveraging IP rights.

XORTX Therapeutics Inc. announces that further to its press releases of March 11 and April 30, 2024, the Company has received TSX Venture Exchange approval to amend the terms of the balance of outstanding common share purchase warrants that were issued on October 15, 2021.

Telix Pharmaceuticals Limited announces that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol “TLX”.

Cytokinetics, Incorporated announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium , May 17th, 2024 at the Mission Bay Conference Center in San Francisco.

Assertio Holdings, Inc. announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the “Units”) at a price of $0.10 per Unit for gross proceeds of up to $1,000,000 (the “Offering”).